N-(3-(2-amino-6,6-difluoro-4,4A,5,6,7,7A-hexahydro-cyclopenta[E][1,3]oxazin-4-yl)-phenylamides as BACE1 inhibitors

A pharmaceutical composition comprising a therapeutically effective amount of a compound of formula I

• wherein
• R1 is selected from the group consisting of
• i) aryl,
• ii) aryl substituted by 1-4 substituents individually selected from cyano, cyano-C1-6-alkyl, halogen, halogen-C1-6-alkoxy, halogen-C1-6-alkyl, C1-6-alkoxy, C1-6-alkoxy-C1-6-alkyl, C2-6-alkynyl-C1-6-alkoxy, C2-6-alkynyl and C1-6-alkyl,
• iii) heteroaryl, and
• iv) heteroaryl substituted by 1-4 substituents individually selected from C3-6-cycloalkyl-C1-6-alkoxy, C3-6-cycloalkyl-C1-6-alkyl, cyano, cyano-C1-6-alkyl, halogen, halogen-C1-6-alkoxy, halogen-C1-6-alkyl, C1-6-alkoxy, C1-6-alkoxy-C1-6-alkyl, C2-6-alkynyl-C1-6-alkoxy, C2-6-alkynyl and C1-6-alkyl;
• R2 is selected from the group consisting of
• i) hydrogen,
• ii) C1-6-alkyl, and
• iii) halogen;
• R3 is selected from the group consisting of
• i) C1-6-alkyl and
• ii) halogen-C1-6-alkyl;
• R4 is selected from the group consisting of
• i) hydrogen and
• ii) C1-6-alkyl;
• and
• R5 is selected from the group consisting of
• i) hydrogen,
• ii) C1-6-alkyl and
• iii) halogen-C1-6-alkyl;
• or a pharmaceutically acceptable salt thereof and a pharmaceutically acceptable carrier.